{"id":"varenicline-var","safety":{"commonSideEffects":[{"rate":"30","effect":"Nausea"},{"rate":"20","effect":"Insomnia"},{"rate":"13","effect":"Abnormal dreams"},{"rate":"13","effect":"Headache"},{"rate":"10","effect":"Dizziness"},{"rate":"8","effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL1076903","moleculeType":"Small molecule","molecularWeight":"211.27"},"_dailymed":{"setId":"29b6b4ca-aeef-1295-e063-6394a90a21b9","title":"VARENICLINE (VARENICLINE TARTRATE) TABLET, FILM COATED [MARLEX PHARMACEUTICALS, INC.]"},"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Varenicline binds with high affinity and selectivity to the alpha-4 beta-2 nicotinic receptor in the brain. As a partial agonist, it provides modest dopamine release to reduce withdrawal symptoms while simultaneously blocking nicotine from binding to and activating the same receptor, thereby diminishing the reinforcing effects of smoking.","oneSentence":"Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:56:08.241Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Smoking cessation in adults"}]},"trialDetails":[{"nctId":"NCT07099638","phase":"PHASE2","title":"Trial of Varenicline With Nicotine Lozenges and a Smartphone Medication Adherence Intervention for Smoking Cessation","status":"NOT_YET_RECRUITING","sponsor":"University of Oklahoma","startDate":"2026-03","conditions":"Smoking Cessation","enrollment":496},{"nctId":"NCT04490057","phase":"PHASE4","title":"A Smart Approach to Treating Tobacco Use Disorder in Persons Living With HIV","status":"COMPLETED","sponsor":"Yale University","startDate":"2020-07-27","conditions":"Tobacco Use Cessation","enrollment":323},{"nctId":"NCT06780215","phase":"PHASE2","title":"Efficacy of Varenicline Tartrate in Treating Frequent Premature Ventricular Contractions","status":"COMPLETED","sponsor":"Yihan Chen","startDate":"2025-02-17","conditions":"Premature Ventricular Contraction (PVC)","enrollment":116},{"nctId":"NCT03059563","phase":"PHASE1","title":"Dopamine D2/D3 Receptor Upregulation by Varenicline in Methamphetamine Users","status":"TERMINATED","sponsor":"University of California, Los Angeles","startDate":"2018-01-11","conditions":"Dopamine D2/3 Receptor Availability, Cognitive Function, Methamphetamine Abuse","enrollment":62},{"nctId":"NCT03722966","phase":"PHASE2","title":"Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)","status":"TERMINATED","sponsor":"University of Oklahoma","startDate":"2020-01-07","conditions":"Smoking Cessation","enrollment":34},{"nctId":"NCT04249882","phase":"PHASE2","title":"A Novel Human Lab Model for Screening AUD Medications","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2020-01-28","conditions":"Alcohol Use Disorder","enrollment":53},{"nctId":"NCT03897439","phase":"PHASE3","title":"Individualizing Pharmacotherapy for African American Smokers","status":"COMPLETED","sponsor":"University of Kansas Medical Center","startDate":"2019-05-01","conditions":"Smoking Cessation","enrollment":392},{"nctId":"NCT02698215","phase":"PHASE2","title":"Combining Varenicline and Naltrexone for Smoking Cessation","status":"COMPLETED","sponsor":"University of California, Los Angeles","startDate":"2016-05","conditions":"Nicotine Dependence, Alcohol Use Disorder","enrollment":165},{"nctId":"NCT02551692","phase":"NA","title":"Effects of Smoking Environments on Craving and Smoking (CameraCue2.0)","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-01","conditions":"Cigarette Smoking","enrollment":125},{"nctId":"NCT00756275","phase":"NA","title":"Varenicline and Motivational Advice for Smokers With Substance Use Disorders","status":"COMPLETED","sponsor":"Brown University","startDate":"2009-01","conditions":"Smoking Cessation, Nicotine Dependence","enrollment":158},{"nctId":"NCT00781755","phase":"PHASE4","title":"Treating Schizophrenic Smokers: Effects on Craving, Cues and Withdrawal","status":"WITHDRAWN","sponsor":"VA Boston Healthcare System","startDate":"","conditions":"Tobacco Use Disorder","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":38,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Varenicline (VAR)","genericName":"Varenicline (VAR)","companyName":"University of Oklahoma","companyId":"university-of-oklahoma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Varenicline is a partial agonist at the alpha-4 beta-2 nicotinic acetylcholine receptor that reduces nicotine cravings and blocks the rewarding effects of smoking. Used for Smoking cessation in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}